The Oncology Institute

TOI

Market cap $280M

Overview Fund Activity

2.99 USD

-0.01

0.33%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

2.97

-0.02

0.67%

1 day

-0.33%

5 days

-4.17%

1 month

-25.99%

3 months

27.78%

6 months

326.53%

Year to date

919.09%

1 year

930.68%

5 years

-70.91%

10 years

-69.18%

About: The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services. Majority of revenue is from patients services.

Employees: 825

Healthcare Medical Care Facilities

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

600% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 6

340% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 5

212% more capital invested

Capital invested by funds: $19.3M [Q1] → $60.1M (+$40.8M) [Q2]

86% more funds holding

Funds holding: 42 [Q1] → 78 (+36) [Q2]

9.59% more ownership

Funds ownership: 22.31% [Q1] → 31.9% (+9.59%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$6

101% upside

Avg. target

$6

101% upside

High target

$6

101% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

B. Riley Securities

Yuan Zhi

$6

Buy

Initiated

16 Jul 2025

See Analyst Rankings

Financial journalist opinion

The Oncology Institute Launches Lung Cancer Center of Excellence in Florida Led by International Oncology Expert Dr. Edgardo Santos

CERRITOS, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute of Hope and Innovation (NASDAQ: TOI), a leading value-based oncology practice, today announced the launch of its Lung Cancer Center of Excellence in Fort Lauderdale, Florida. The new center will be led by world-renowned thoracic oncologist Dr. Edgardo S. Santos Castillero, whose career has been defined by groundbreaking research, clinical excellence, and a deep commitment to patient care.

The Oncology Institute Launches Lung Cancer Center of Excellence in Florida Led by International Oncology Expert Dr. Edgardo Santos

The Oncology Institute: A Promising Company In A Growing Sector

The Oncology Institute has achieved a strong growth in revenue in the previous years, justifying its stock price movement. We believe TOI will still be able to grow in the coming quarters while currently trading at a discount. Risks remain high, warranting careful positioning.

The Oncology Institute: A Promising Company In A Growing Sector

The Oncology Institute, Inc. (TOI) Q2 2025 Earnings Call Transcript

The Oncology Institute, Inc. (NASDAQ:TOI ) Q2 2025 Earnings Conference Call August 13, 2025 5:00 PM ET Company Participants Daniel Virnich - CEO & Executive Director Mark Hueppelsheuser - Corporate Participant General Counsel - Corporate Participant Robert Carter - Chief Financial Officer Conference Call Participants David Michael Larsen - BTIG, LLC, Research Division Robert Michael LeBoyer - NOBLE Capital Markets, Inc., Research Division Yuan Zhi - B. Riley Securities, Inc., Research Division Operator Ladies and gentlemen, greetings, and welcome to the Oncology Institute Second Quarter 2025 Earnings Call.

The Oncology Institute, Inc. (TOI) Q2 2025 Earnings Call Transcript

The Oncology Institute Reports Second Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance

CERRITOS, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended June 30, 2025.

The Oncology Institute Reports Second Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance

The Oncology Institute Announces Changes to Board of Directors

Richard Barasch to Retire; Anne McGeorge Brings Extensive Financial Experience to Role as New Chairman Richard Barasch to Retire; Anne McGeorge Brings Extensive Financial Experience to Role as New Chairman

The Oncology Institute Announces Changes to Board of Directors

The Oncology Institute Names Kristin England as Chief Administrative Officer

CERRITOS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, announced today that Kristin England has joined the organization as Chief Administrative Officer (CAO), effective July 7, 2025. In this newly established role, England will oversee Enterprise Central Business Operations and Technology Strategy and Enablement across TOI's expanding national footprint.

The Oncology Institute Names Kristin England as Chief Administrative Officer

The Oncology Institute and SilverSummit Healthplan Partner to Provide Oncology Care to Over 80,000 Medicaid Members in Nevada

CERRITOS, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, announced today that effective July 1, it will be the exclusive oncology provider for over 80,000 Medicaid patients associated with SilverSummit Healthplan in Nevada. TOI is known for bringing state-of-the-art cancer care to the communities it serves, and their presence in the Las Vegas market will provide enhanced access to care and high-level services to the important Medicaid population here.

The Oncology Institute and SilverSummit Healthplan Partner to Provide Oncology Care to Over 80,000 Medicaid Members in Nevada

The Oncology Institute set to join the Russell 2000® and Russell 3000® Indexes

CERRITOS, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, today announced that it will join the Russell 2000® and Russell 3000® after the 2025 Russell indexes annual reconstitution, effective after the US market closes on June 27, according to a preliminary list of additions posted on May 23.

The Oncology Institute set to join the Russell 2000® and Russell 3000® Indexes

The Oncology Institute, Inc. (TOI) Q1 2025 Earnings Call Transcript

The Oncology Institute, Inc. (NASDAQ:TOI ) Q1 2025 Earnings Conference Call May 14, 2025 5:00 PM ET Company Participants Mark Hueppelsheuser - General Counsel Daniel Virnich - Chief Executive Officer Rob Carter - Chief Financial Officer Conference Call Participants David Larsen - BTIG Yuan Zhi - B. Riley Bill Sutherland - The Benchmark Company Robert LeBoyer - NOBLE Capital Markets Operator Good afternoon and welcome to The Oncology Institute's First Quarter 2025 Earnings Conference Call.

The Oncology Institute, Inc. (TOI) Q1 2025 Earnings Call Transcript

The Oncology Institute Welcomes Dr. Jeff Langsam as Chief Clinical Officer

CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, announced today that Dr. Jeffrey Langsam will assume the role of enterprise Chief Clinical Officer effective May 13th, 2025. The CCO role will oversee therapeutics including pathway and procurement decisions, utilization management, and MSO practice clinical engagement. Dr. Langsam joins TOI from Cigna Healthcare, where he was the National Director of Oncology and a Senior Medical Director in the Specialty Pharmacy Division. He previously served as a Regional Medical Director at Aetna, and was clinical faculty at the University of Connecticut where he was a practicing oncologist for many years.

The Oncology Institute Welcomes Dr. Jeff Langsam as Chief Clinical Officer

See News Rankings

Charts implemented using Lightweight Charts™